The first therapeutic approach to block leptin signaling was reported in 1997 by Verploegen et al., who demonstrated how the substitution of arginine with glutamine at position 128 of human leptin completely inhibits leptin/leptin receptor binding and blocks its biological activity, showing a promising anti-cancer effect [236]. The gene discussed is LEPR; the disease is cancer.